HTLV-1 myelopathy after renal transplant and antiviral prophylaxis: the need for screening

• Published in: Journal of neurovirology Vol. 24; no. 4; pp. 523 - 525
• Main Authors: Moreno-Ajona, David, Yuste, José Ramón, Martín, Paloma, Gállego Pérez-Larraya, Jaime
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2018
• Subjects: Biomedical and Life Sciences; Biomedicine; Case Report; Immunology; Infectious Diseases; Neurology; Neurosciences; Virology; Myelopathy; HTLV-1; Kidney transplant; Viral infection
• ISSN: 1355-0284; 1538-2443
• DOI: 10.1007/s13365-018-0627-3

The human T-lymphotropic virus type 1 (HTLV-1) is a RNA retrovirus that infects a minimum of 5–10 million people worldwide. Transmission by cell-containing blood products and solid organ transplantation has been reported. Clinical disease occurs in about 5–10% of infected individuals and consists mainly in adult T cell leukemia and HTLV-1-associated myelopathy (HAM). We present a 54-year-old woman who underwent kidney transplant from cadaveric donor in March 2015. Donor also underwent cornea extraction for another recipient (corneal transplant protocol includes HTLV-1/2 serology). Twenty-four hours after completion of kidney transplant donor, HTLV-1 serology was revealed positive. Following experts’ recommendations, once donor seropositivity was demonstrated, antiviral prophylaxis including zidovudine and raltegravir was initially given to our patient, in spite of which the patient developed HAM. Once the diagnosis of HAM was established, antiretroviral therapy was restarted, and intravenous pulses of methylprednisolone were periodically administered with transient initial improvement. Later on, the patient experienced neurological deterioration becoming wheelchair dependent. Since the occurrence of this case, HTLV-1 screening has become mandatory for solid organ transplantation in the Spanish province of Navarra, and the same should happen worldwide.